期刊
EXPERT REVIEW OF VACCINES
卷 10, 期 10, 页码 1415-1433出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.11.120
关键词
antibody-mediated protection; formalin-inactivated vaccine; immunopathology; pediatric vaccine; prime-boost strategies; respiratory syncytial virus vaccines; T-cell-mediated protection; vaccine vectors
类别
资金
- NIH, NIAID [P01-AI-054955, R01-AI088729, R01-AI78819]
- NCI [P30-CA21765]
- American Lebanese Syrian Associated Charities
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract viral disease in infants and young children. Presently, there are no explicit recommendations for RSV treatment apart from supportive care. The virus is therefore responsible for an estimated 160,000 deaths per year worldwide. Despite half a century of dedicated research, there remains no licensed vaccine product. Herein are described past and current efforts to harness innate and adaptive immune potentials to combat RSV. A plethora of candidate vaccine products and strategies are reviewed. The development of a successful RSV vaccine may ultimately stem from attention to historical lessons, in concert with an integral partnering of immunology and virology research fields.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据